Secondary Prevention with “Cardio-diabetes”
1. “Pump, pipes and filters”- Do SGLT2i`s & GLP-1 agonists cover it all?
a. Rethinking Cardiovascular Risk Reduction
b. HFpEF/HFrEF + Diabetes
2. Revascularization in stable CAD-not quite so simple...
a. “Bridging the fragile gap” of CABG & PCI